Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
2005-02-15
2005-02-15
Meller, Michael (Department: 1654)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Reexamination Certificate
active
06855344
ABSTRACT:
A composition including an aliquot of the herbHerba Epimedii; and an aliquot of at least three supplemental herbs selected from the group consisting ofFructus Rosae Laevigatae; Fructus Rubi; Fructus Psoralea; Radix Morindae Officinalis; Fructus Schisandrac Chinensis; Fructus Ligustri Lucidi; Semen Cuscutae; andRadix Astragali. A composition including icariin; ursolic acid; ellagic acid; psoralen; deoxyschizandrin; oleanolic acid; quercetin; aslvagaloside; and an extract of the herbRadix Morindae Officinalis. Methods including administering a composition directed at treatment of various kidney disorders or the promotion of kidney health and to the overall health of the kidney, including the use of a composition in the treatment of prostate cancer, prophylatic prostate health, reduction of polyuria, incontinence, proteinuria, as well as for sexual satisfaction.
REFERENCES:
patent: 5665393 (1997-09-01), Chen et al.
patent: 6197309 (2001-03-01), Wheeler
patent: 1054370 (1991-11-01), None
patent: 1065489 (1992-10-01), None
patent: 1078903 (1993-12-01), None
patent: 1085785 (1994-04-01), None
patent: 1133185 (1996-10-01), None
patent: 1184659 (1998-06-01), None
patent: 1206601 (1999-02-01), None
Craft, N, et al., “Mechanistic concepts in androgen-dependence of prostate cancer,” Cancer & Metastasis Reviews, 17(4):421-7, 1998-99 (Abstract).
Crawford, ED, “Challenges in the management of prostate cancer,” British Journal of Urology, 70 Suppl 1:33-8, Nov. 1992 (Abstract).
Eisenberg, DM, et al., “Unconventional medicine in the United States. Prevalence, costs, and patterns of use,” New England Journal of Medicine, 328(4):246-52, Jan. 1993 (Abstract).
Fenton, MA, et al., “Functional characterization of mutant androgen receptors from androgen-independent prostate cancer,” Clinical Cancer Research, 3(8):1383-8, Aug. 1997 (Abstract).
Garnick, MB, “Prostate cancer: screening, diagnosis, and management,” Annals of Internal Medicine, 118(10):804, May 1993.
Isaacs, JT, et al., “The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue,” Seminars in Cancer Biology, 5(5):391-400, Oct. 1994.
Jenster, G., “The role of the androgen receptor in the development and progression of prostate cancer,” Seminars in Oncology, 26(4):407-21, Aug. 1999 (Abstract).
Kyprianou, N, “Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death,” Prostate, 25(2):66-75, Aug. 1994.
Moyad, MA, “Alternative therapies for advanced prostate cancer,” Urologic Clinics of North America, 26(2):413-7, May 1999 (Abstract).
Pelletier, KR, “Current trends in the integration and reimbursement of complementary and alternative medicine by managed care organizations (MCOs) and insurance providers: 1998 update and cohort analysis,” American Journal of Health Promotion, 14(2):125-33, Nov.-Dec. 1997 (Abstract).
Pelletier, KR, “Current trends in the integration and reimbursement of complementary and alternative medicine by managed care, insurance carriers, and hospital providers,” American Journal of Health Promotion, 12(2):112-22, Nov.-Dec. 1997 (Abstract).
Sadar, MD, “Prostate cancer: molecular biology of early progression to androgen independence,” Endocine-Related Cancer, 6(4):487-502, Dec. 1999 (Abstract).
Schulman, CC, “Prevention of prostate cancer,” Scandinavian Journal of Urology & Nephrology, Supplementum, (205):50-61, 2000 (Abstract).
Tilley, WD, “Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence,” Clinical Cancer Research, 2(2):277-85, Feb. 1996 (Abstract).
Visakorpi, T, “In vivo amplification of the androgen receptor gene and progression of human prostate cancer,” Nature Genetics, 9(4):401-6, Apr. 1995 (Abstract).
Akakura, K, et al., “Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate,” Urology, vol. 45, No. 4, Apr. 1995, pp. 700-705.
Craft, N, et al., “A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2
eu tyrosine kinase,” Nature Medicine, vol. 5, No. 3, Mar. 1999, pp. 280-285.
Eisenberg, DM, et al., “Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey,” Journal of the American Medical Association, vol. 280(18), Nov. 1998, pp. 1569-1575.
Culig, Z, et al., “Expression, structure, and function of androgen receptor in advanced prostatic carcinoma,” The Prostate, 35:63-70, 1998.
Tilley, W, et al., “Hormones and cancer: new insight, new challenges,” Trends in Endocrinology & Metabolism, vol. 12, No. 5, July 2001, pp. 186-188.
Blakely , Sokoloff, Taylor & Zafman LLP
Integrated Chinese Medicine Holdings, Ltd.
Meller Michael
LandOfFree
Compositions and methods for prostate and kidney health and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for prostate and kidney health and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for prostate and kidney health and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3477816